# Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer

> **NCT02343835** · NA · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DEVICE:** NanoKnife LEDC System

## Key facts

- **NCT ID:** NCT02343835
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-05-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343835, "Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02343835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*